RELAPSED

作品数：95被引量：150H指数：7
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：关涛苏丽萍马莉赵瑾王晶荣更多>>
相关机构：上海市第一人民医院绍兴文理学院绍兴市人民医院浙江省人民医院更多>>
相关期刊：《Asian Journal of Andrology》《Journal of Integrative Medicine》《Open Journal of Blood Diseases》《Cellular & Molecular Immunology》更多>>
相关基金：国家自然科学基金北京市自然科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Frontiers of Medicinex
共 条 记 录，以下是1-4
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)被引量：9
《Frontiers of Medicine》2022年第5期766-772,共7页Jianhua Shi Ying Cheng Qiming Wang Kai Li Lin Wu Baohui Han Gongyan Chen Jianxing He Jie Wang Haifeng Qin Xiaoling Li 
This study was supported by the Jilin Provincial Healthand Family Planning Commission (No.2019J077);the Science and Technology Agency of Jilin Provincial Project (No.20200201518JC)。
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy and safety of anlotinib as third- or further-line therapy in patients...
关键词：anlotinib CHEMOTHERAPY short-term relapsed small-cell lung cancer 
Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion被引量：1
《Frontiers of Medicine》2021年第5期728-739,共12页Tingting Han Yuqian Sun Yang Liu Chenhua Yan Yu Wang Lanping Xu Kaiyan Liu Xiaojun Huang Xiaohui Zhang 
This work was supported by the National Natural Science Foundation of China(No.81670116);Key Program of National Natural Science Foundation of China(No.81730004);Beijing Natural Science Foundation(No.7171013);Foundation for Innovative Research Groups of the National Natural Science Foundation of China(No.81621001).
Relapse is the main problem after allogeneic hematopoietic stem cell transplantation(allo-HSCT).The outcome of a second allo-HSCT(HSCT2)for relapse post-HSCT has shown promising results in some previous studies.Howeve...
关键词：second hematopoietic stem cell transplantation acute leukemia RELAPSE chemotherapy modified donor lymphocyte infusion 
Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy
《Frontiers of Medicine》2020年第6期786-791,共6页Lili Zhou Ping Li Shiguang Ye Xiaochen Tang Junbang Wang Jie Liu Aibin Liang 
This study was supported by grants from the Municipal Hospital Frontier Technology Joint Project of Shanghai City(No.SHDC12015108);the National Natural Science Foundation of China(Nos.81830004 and 31301118).
Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T(CAR-T)cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma(r/r NHL)have not been well characterized.In ...
关键词：anti-CD19 chimeric antigen receptor T cell soft tissue bone marrow relapsed or refractory non-Hodgkin lymphoma 
Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
《Frontiers of Medicine》2020年第6期811-815,共5页Ping Li Ningxin Dong Yu Zeng Jie Liu Xiaochen Tang Junbang Wang Wenjun Zhang Shiguang Ye Lili Zhou Alex Hongsheng Chang Aibin Liang 
This study was supported by grants from the Shanghai Municipal Hospital New Frontier Technology Joint Research Project(No.SHDC12015108);the National Natural Science Foundation of China(Nos.81830004,31301118,and 81272325);the Fundamental Research Funds for the Central Universities(No.22120170004).
Mantle cell lymphoma(MCL)is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents,such as proteasome inhibitors,immunomodulatory drugs,and inhibitors of B cell lymphoma-2 and Bruton’s t...
关键词：anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部